Pharmacokinetic behavior of rituximab: A study of different schedules of administration for heterogeneous clinical settings

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 785-792

  Regazzi, Mario B ^a   Iacona, Isabella ^a   Avanzini, Maria Antonietta ^a   Arcaini, Luca ^a   Merlini, Gianpaolo ^a   Perfetti, Vittorio ^a   Zaja, Francesco ^b   Montagna, Michela ^a   Morra, Enrica ^c   Lazzarino, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cancer chemotherapy; Rituximab; Therapeutic drug monitoring

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AMYLOIDOSIS; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; B LYMPHOCYTE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLICULAR LYMPHOMA; HUMAN; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; STEADY STATE; STEM CELL; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METHODOLOGY;

AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, FOLLICULAR; METABOLIC CLEARANCE RATE;

EID: 33646833094     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000184162.60197.c1     Document Type: Conference Paper

References (27)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
2. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450-454.
3. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody Rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003;63:534-540.
4. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol. 2001;40:3-16.
5. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol. 1999;26(Suppl 14):74-78.
6. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673-683.
7. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 antibody (IDEC-C2B8) sensitises a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
8. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800-809.
9. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
10. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol. 2000;27(Suppl 12):9-16.
11. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10:655-661.
12. Hainsworth JD, Litchy S, Burris HA3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
13. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
14. Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica. 2001;86:951-958.
15. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864-869.
16. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immunochemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol. 2002;116:229-235.
17. Kosmas C, Stamatopoulos K, Stavroyianni N, et al. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 2002;16:2004-2015.
18. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
19. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with Rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002;87:189-195.
20. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit. 2000;22:295-301.
21. Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and Rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856-862.
22. Grillo-Lopez. Rituximab (Rituxan®/MabThera®): the first decade (1993-2003). Expert Rev Anticancer Ther. 2003;3:767-779.
23. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in relapsed B-cell lymphoma. Ann Oncol. 1998;9:527-534.
24. Bjornsson TD, Wagner JA, Donhahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003;43:943-967.
25. McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
26. Tobinai K, Igarashi T, Ithoh K, et al. Japanese multicenter phase II and pharmacokinetic study of Rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15:821-830.
27. Gordan L,Grow W. Braylan RC, et al. A phase II trial of individualized pharmacokinetic dosing of Rituximab maintenance for patients with CD-20 positive lymphoproliferative disorders [abstract]. ASH-Philadelphia. Blood. 2002;100:362.